|
rs113488022
|
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
UNIPROT |
Updated guidelines for biomarker testing in colorectal carcinoma: a national consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.
|
25373533 |
2015 |
|
rs113488022
|
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
UNIPROT |
RAS testing of colorectal carcinoma—a guidance document from the Association of Clinical Pathologists Molecular Pathology and Diagnostics Group.
|
24996433 |
2014 |
|
rs113488022
|
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
UNIPROT |
Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update.
|
23852704 |
2014 |
|
rs113488022
|
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
UNIPROT |
Multitarget stool DNA testing for colorectal-cancer screening.
|
25006736 |
2014 |
|
rs113488022
|
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
UNIPROT |
Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?
|
23429431 |
2013 |
|
rs113488022
|
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
UNIPROT |
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making.
|
23012255 |
2012 |
|
rs113488022
|
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
UNIPROT |
Guidelines for biomarker testing in colorectal carcinoma (CRC): a national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM).
|
22855150 |
2012 |
|
rs113488022
|
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
UNIPROT |
NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology.
|
22138009 |
2011 |
|
rs113488022
|
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
UNIPROT |
National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers.
|
19042984 |
2008 |
|
rs113488022
|
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
UNIPROT |
ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer.
|
17060676 |
2006 |
|
rs180177034
|
|
Cardio-facio-cutaneous syndrome
|
|
0.810 |
GeneticVariation
|
UNIPROT |
2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC).
|
25173338 |
2014 |
|
rs180177035
|
|
Cardio-facio-cutaneous syndrome
|
|
0.810 |
GeneticVariation
|
UNIPROT |
2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC).
|
25173338 |
2014 |
|
rs180177037
|
|
Cardio-facio-cutaneous syndrome
|
|
0.810 |
GeneticVariation
|
UNIPROT |
2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC).
|
25173338 |
2014 |
|
rs397507466
|
|
Cardio-facio-cutaneous syndrome
|
|
0.810 |
GeneticVariation
|
UNIPROT |
2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC).
|
25173338 |
2014 |
|
rs121913338
|
|
Lymphoma, Non-Hodgkin, Familial
|
|
0.800 |
GeneticVariation
|
UNIPROT |
BRAF mutations in non-Hodgkin's lymphoma.
|
14612909 |
2003 |
|
rs121913341
|
|
Cardio-facio-cutaneous syndrome
|
|
0.800 |
GeneticVariation
|
UNIPROT |
Germline BRAF mutations in Noonan, LEOPARD, and cardiofaciocutaneous syndromes: molecular diversity and associated phenotypic spectrum.
|
19206169 |
2009 |
|
rs121913341
|
|
Cardio-facio-cutaneous syndrome
|
|
0.800 |
GeneticVariation
|
UNIPROT |
Mutation and phenotypic spectrum in patients with cardio-facio-cutaneous and Costello syndrome.
|
18042262 |
2008 |
|
rs121913341
|
|
Cardio-facio-cutaneous syndrome
|
|
0.800 |
GeneticVariation
|
UNIPROT |
Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome.
|
16474404 |
2006 |
|
rs121913341
|
|
Cardio-facio-cutaneous syndrome
|
|
0.800 |
GeneticVariation
|
UNIPROT |
Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome.
|
16439621 |
2006 |
|
rs121913348
|
|
Colorectal Carcinoma
|
|
0.800 |
GeneticVariation
|
UNIPROT |
Evidence That GRIN2A Mutations in Melanoma Correlate with Decreased Survival.
|
24455489 |
2014 |
|
rs121913348
|
|
Colorectal Carcinoma
|
|
0.800 |
GeneticVariation
|
UNIPROT |
Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas.
|
23263490 |
2013 |
|
rs121913348
|
|
Colorectal Carcinoma
|
|
0.800 |
GeneticVariation
|
UNIPROT |
Protein arginine methyltransferase 5 regulates ERK1/2 signal transduction amplitude and cell fate through CRAF.
|
21917714 |
2011 |
|
rs121913348
|
|
Colorectal Carcinoma
|
|
0.800 |
GeneticVariation
|
UNIPROT |
Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status.
|
12198537 |
2002 |
|
rs121913351
|
|
Carcinoma of lung
|
|
0.800 |
GeneticVariation
|
UNIPROT |
Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the study of lung cancer/association for molecular pathology guideline.
|
25311215 |
2014 |
|
rs121913351
|
|
Carcinoma of lung
|
|
0.800 |
GeneticVariation
|
UNIPROT |
Non-small cell lung cancer and precision medicine: a model for the incorporation of genomic features into clinical trial design.
|
24846033 |
2014 |